These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31689133)

  • 21. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.
    Lin YJ; Lin HC; Yang YF; Chen CY; Lu TH; Liao CM
    Int J Infect Dis; 2020 Aug; 97():135-142. PubMed ID: 32474203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
    Lorenzana SB; Hughes MD; Grinsztejn B; Collier AC; Luz PM; Freedberg KA; Wood R; Levison JH; Mugyenyi PN; Salata R; Wallis CL; Weinstein MC; Schooley RT; Walensky RP
    AIDS; 2012 Jun; 26(9):1083-93. PubMed ID: 22343964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
    Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana.
    Enane LA; Lowenthal ED; Arscott-Mills T; Matlhare M; Smallcomb LS; Kgwaadira B; Coffin SE; Steenhoff AP
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1320-1325. PubMed ID: 27725042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
    Foster S; Godfrey-Faussett P; Porter J
    AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.
    Lawrence DS; Muthoga C; Meya DB; Tugume L; Williams D; Rajasingham R; Boulware DR; Mwandumba HC; Moyo M; Dziwani EN; Maheswaran H; Kanyama C; Hosseinipour MC; Chawinga C; Meintjes G; Schutz C; Comins K; Bango F; Muzoora C; Jjunju S; Nuwagira E; Mosepele M; Leeme T; Ndhlovu CE; Hlupeni A; Shamu S; Boyer-Chammard T; Molloy SF; Youssouf N; Chen T; Shiri T; Jaffar S; Harrison TS; Jarvis JN; Niessen LW;
    Lancet Glob Health; 2022 Dec; 10(12):e1845-e1854. PubMed ID: 36400090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.
    Walensky RP; Borre ED; Bekker LG; Resch SC; Hyle EP; Wood R; Weinstein MC; Ciaranello AL; Freedberg KA; Paltiel AD
    Ann Intern Med; 2016 Sep; 165(5):325-33. PubMed ID: 27240120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss to follow-up among patients diagnosed with spinal tuberculosis at a tertiary hospital in Western Cape Province, South Africa: A retrospective cohort study.
    Mann TN; Davis JH; Dyers R
    S Afr Med J; 2020 Mar; 110(4):284-290. PubMed ID: 32657739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.